Discordant effects of rasagiline doses in Parkinson disease

Nature Reviews Neurology

Volumn 6, Issue 7, 2010, Pages

  Deftereos, Spyros N ^a   Andronis, Christos A ^a  

^a Biovista Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; RASAGILINE; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT;

DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS;

DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; INDANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 77954858931     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.2-c1     Document Type: Letter

References (6)

1. Sampaio, C. & Ferreira, J. J. Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression. Nat. Rev. Neurol. 6, 126-128 (2010).
2. Youdim, M. B. Rasagiline in Parkinson's disease. N. Engl. J. Med. 362, 657-658 (2010).
3. Olanow, C. W. et al. ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268-1278 (2009).
4. Blandini, F., Armentero, M. T., Fancellu, R., Blaugrund, E. & Nappi, G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. 187, 455-459 (2004).
5. Rabey, J. M. et al. Rasagiline Study Group. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a doubleblind study as adjunctive therapy to levodopa. Clin. Neuropharmacol. 23, 324-330 (2000).
6. Ou, X. M. et al. Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox. Res. 16, 148-159 (2009).